2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1561

Associations of HLA-DRB1 Haplotypes with Disease Characteristics and All-Cause Mortality in Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 1350

Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease: 8 Years of Experience

Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

9:00AM-11:00AM: Abstract Number: 1096

Augmentation of Wnt Signaling By IL-1β in Fibroblast-like Synoviocytes

Biology and Pathology of Bone and Joint - Poster II

9:00AM-11:00AM: Abstract Number: 1214

Autoantibody Reactivities Correlated with SLE Disease Activity Identified By the SLE-key® iCHIP® Platform

Genetics, Genomics and Proteomics - Poster II

9:00AM-11:00AM: Abstract Number: 1833

Autoantibody Response to TROVE2 in Systemic LUPUS Erythematosus Patients

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1326

Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthropathy, Following Lyme Disease

Infection-related Rheumatic Disease - Poster

9:00AM-11:00AM: Abstract Number: 1172

Azathioprine and Mycophenolate Mofetil Adherence in a Nationwide Medicaid Cohort with Systemic Lupus Erythematosus

Epidemiology and Public Health - Poster II

9:00AM-11:00AM: Abstract Number: 1913

B Cell Depletion Therapy Impact CD8 T Cells in ANCA-Associated Vasculitis

T Cell Biology and Targets in Autoimmune Disease - Poster Session I

9:00AM-11:00AM: Abstract Number: 1080

B-Cell Clonal Expansions in Parotid Glands of Sjogren’s Patients Are Associated with Increased Numbers of N-Glycosylation Motifs in the Immunoglobulin Heavy Chain Genes

B Cell Biology and Targets in Autoimmune Disease - Poster I: SLE and Sjögren's

9:00AM-11:00AM: Abstract Number: 1417

Back to Feeling Normal Again: Patients with Rheumatoid Arthritis in Remission

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1076

BAFF Receptor Antagonists Suppress Differentiation of B Cells in Vitro and Are Drug Candidates for Primary SjöGren’s Syndrome

B Cell Biology and Targets in Autoimmune Disease - Poster I: SLE and Sjögren's

9:00AM-11:00AM: Abstract Number: 1584

Bari-00074565

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1593

Baricitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1702

Baseline Patient Characteristics Associated with Response to Biologic Therapy in Patients with Psoriatic Arthritis Enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1652

Basement Membrane Remodeling Is Significantly Increased with Rheumatoid Arthritis and Suppressed By IL6 Inhibition: Analysis of Two Phase III Clinical Trial

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

«Previous Page
1
…
6
7
8
9
10
…
68
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.